{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T23:38:39Z","timestamp":1788219519236,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T00:00:00Z","timestamp":1589846400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013373","name":"NIHR Oxford Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013373","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Osteogenesis imperfecta, fibrous dysplasia\/McCune-Albright syndrome and X-linked hypophosphatemia are three rare musculoskeletal diseases characterised by bone deformities, frequent fractures and pain. Little high-quality research exists on appropriate treatment and long-term management of these conditions in adults. This is further worsened by limited research funding in rare diseases and a general mismatch between the existing research priorities and those of the patients. This partnership adopted the James Lind Alliance approach to identify the top 10 research priorities for rare musculoskeletal diseases in adults through joint patient, carer and healthcare professional collaboration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The initial survey for question collection recruited 198 respondents, submitting a total of 988 questions. 77% of the respondents were patients with a rare musculoskeletal disease. Following out-of-scope question exclusion, repeating query grouping and scientific literature check for answers, 39 questions on treatment and long-term management remained. In the second public survey, 220 respondents, of whom 85% were patients with a rare musculoskeletal disease, their carers, relatives or friends, prioritised these uncertainties, which allowed selection of the top 25. In the last stage, patients, carers and healthcare professionals gathered for a priority setting workshop to reach a consensus on the final top 10 research priorities. These focus on the uncertainties surrounding appropriate treatment and holistic long-term disease management, highlighting several aspects indirect to abnormal bone metabolism, such as extra-skeletal symptoms, psychological care of both patients and their families and disease course through ageing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This James Lind Alliance priority setting partnership is the first to investigate rare bone diseases. The priorities identified here were developed jointly by patients, carers and healthcare professionals. We encourage researchers, funding bodies and other stakeholders to use these priorities in guiding future research for those affected by rare musculoskeletal disorders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-020-01398-5","type":"journal-article","created":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T16:21:30Z","timestamp":1589905290000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Rare musculoskeletal diseases in adults: a research priority setting partnership with the James Lind Alliance"],"prefix":"10.1186","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2477-7565","authenticated-orcid":false,"given":"Gerda","family":"Mickute","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Staley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Delaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Gardiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Hunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Keen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorraine","family":"Lockhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Meade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Ralston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Rush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheela","family":"Upadhyaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Regan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Watts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger M.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Kassim","family":"Javaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,19]]},"reference":[{"issue":"1","key":"1398_CR1","doi-asserted-by":"publisher","first-page":"R13","DOI":"10.1530\/EC-13-0103","volume":"3","author":"A Linglart","year":"2014","unstructured":"Linglart A, Biosse-Duplan M, Briot K, Chaussain C, Esterle L, Guillaume-Czitrom S, et al. Therapeutic management of hypophosphatemic rickets from infancy to adulthood. Endocr Connect. 2014;3(1):R13\u201330.","journal-title":"Endocr Connect"},{"issue":"1","key":"1398_CR2","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13023-019-1102-9","volume":"14","author":"MK Javaid","year":"2019","unstructured":"Javaid MK, Boyce A, Appelman-Dijkstra N, Ong J, Defabianis P, Offiah A, et al. Best practice management guidelines for fibrous dysplasia\/McCune-Albright syndrome: a consensus statement from the FD\/MAS international consortium. Orphanet J Rare Dis. 2019;14(1):139.","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"1398_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2017.52","volume":"3","author":"JC Marini","year":"2017","unstructured":"Marini JC, Forlino A, B\u00e4chinger HP, Bishop NJ, Byers PH, Paepe AD, et al. Osteogenesis imperfecta. Nat Rev Dis Primers. 2017;3(1):1\u201319.","journal-title":"Nat Rev Dis Primers"},{"issue":"9220","key":"1398_CR4","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1016\/S0140-6736(00)02351-5","volume":"355","author":"D Tallon","year":"2000","unstructured":"Tallon D, Chard J, Dieppe P. Relation between agendas of the research community and the research consumer. Lancet. 2000;355(9220):2037\u201340.","journal-title":"Lancet"},{"issue":"9805","key":"1398_CR5","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1016\/S0140-6736(11)61772-8","volume":"378","author":"A Liberati","year":"2011","unstructured":"Liberati A. Need to realign patient-oriented and commercial and academic research. Lancet. 2011;378(9805):1777\u20138.","journal-title":"Lancet"},{"issue":"7650","key":"1398_CR6","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1136\/bmj.39547.586100.80","volume":"336","author":"H Thornton","year":"2008","unstructured":"Thornton H. Patient and public involvement in clinical trials. BMJ. 2008;336(7650):903\u20134.","journal-title":"BMJ"},{"issue":"9912","key":"1398_CR7","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/S0140-6736(13)62229-1","volume":"383","author":"I Chalmers","year":"2014","unstructured":"Chalmers I, Bracken MB, Djulbegovic B, Garattini S, Grant J, G\u00fclmezoglu AM, et al. How to increase value and reduce waste when research priorities are set. Lancet. 2014;383(9912):156\u201365.","journal-title":"Lancet"},{"issue":"1","key":"1398_CR8","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1093\/intqhc\/mzr066","volume":"24","author":"C Mockford","year":"2012","unstructured":"Mockford C, Staniszewska S, Griffiths F, Herron-Marx S. The impact of patient and public involvement on UK NHS health care: a systematic review. Int J Qual Health Care. 2012;24(1):28\u201338.","journal-title":"Int J Qual Health Care"},{"issue":"9449","key":"1398_CR9","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1016\/S0140-6736(04)17494-1","volume":"364","author":"N Partridge","year":"2004","unstructured":"Partridge N, Scadding J. The James Lind Alliance: patients and clinicians should jointly identify their priorities for clinical trials. Lancet. 2004;364(9449):1923\u20134.","journal-title":"Lancet"},{"key":"1398_CR10","unstructured":"JLA Guidebook | James Lind Alliance. Available at: www.jla.nihr.ac.uk\/jla-guidebook\/. Accessed 8 Jan 2020."},{"key":"1398_CR11","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40900-015-0003-x","volume":"1","author":"S Crowe","year":"2015","unstructured":"Crowe S, Fenton M, Hall M, Cowan K, Chalmers I. Patients', clinicians' and the research communities' priorities for treatment research: there is an important mismatch. Res Involv Engagem. 2015;1:2.","journal-title":"Res Involv Engagem"},{"key":"1398_CR12","unstructured":"The PSPs | James Lind Alliance. Available at: www.jla.nihr.ac.uk\/priority-setting-partnerships\/. Accessed 8 Jan 2020."},{"issue":"4","key":"1398_CR13","doi-asserted-by":"publisher","first-page":"e010412","DOI":"10.1136\/bmjopen-2015-010412","volume":"6","author":"Amar Rangan","year":"2016","unstructured":"Rangan A, Upadhaya S, Regan S, Toye F, Rees JL. Research priorities for shoulder surgery: results of the 2015 James Lind Alliance patient and clinician priority setting partnership. BMJ Open. 2016;6(4):e010412.","journal-title":"BMJ Open"},{"issue":"1_suppl","key":"1398_CR14","doi-asserted-by":"publisher","first-page":"65S","DOI":"10.1177\/2192568219832855","volume":"9","author":"Benjamin M. Davies","year":"2019","unstructured":"Davies BM, Khan DZ, Mowforth OD, McNair AGK, Gronlund T, Kolias AG, et al. RE-CODE DCM (REsearch objectives and common data elements for degenerative cervical myelopathy): a consensus process to improve research efficiency in DCM, through establishment of a standardized dataset for clinical research and the definition of the research priorities. Global Spine J. 2019;9(1):65S\u201376S.","journal-title":"Global Spine Journal"},{"issue":"12","key":"1398_CR15","doi-asserted-by":"publisher","first-page":"e030028","DOI":"10.1136\/bmjopen-2019-030028","volume":"9","author":"WJ Sheehan","year":"2019","unstructured":"Sheehan WJ, Williams MA, Paskins Z, Costa ML, Fernandez MA, Gould J, et al. Research priorities for the management of broken bones of the upper limb in people over 50: a UK priority setting partnership with the James Lind Alliance. BMJ Open. 2019;9(12):e030028.","journal-title":"BMJ Open"},{"issue":"10","key":"1398_CR16","doi-asserted-by":"publisher","first-page":"e023301","DOI":"10.1136\/bmjopen-2018-023301","volume":"8","author":"MA Fernandez","year":"2018","unstructured":"Fernandez MA, Arnel L, Gould J, McGibbon A, Grant R, Bell P, et al. Research priorities in fragility fractures of the lower limb and pelvis: a UK priority setting partnership with the James Lind Alliance. BMJ Open. 2018;8(10):e023301.","journal-title":"BMJ Open"},{"issue":"1","key":"1398_CR17","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12969-018-0276-3","volume":"16","author":"CG Schoemaker","year":"2018","unstructured":"Schoemaker CG, Armbrust W, Swart JF, Vastert SJ, van Loosdregt J, Verwoerd A, et al. Dutch juvenile idiopathic arthritis patients, carers and clinicians create a research agenda together following the James Lind Alliance method: a study protocol. Pediatr Rheumatol Online J. 2018;16(1):57.","journal-title":"Pediatr Rheumatol Online J"},{"key":"1398_CR18","unstructured":"Rare Musculoskeletal Diseases in Adulthood | James Lind Alliance. Available at: www.jla.nihr.ac.uk\/priority-setting-partnerships\/rare-musculoskeletal-diseases-in-adulthood\/rare-musculoskeletal-diseases-in-adulthood.htm. Accessed 10 Jan 2020."},{"key":"1398_CR19","unstructured":"Top 10s of priorities for research | James Lind Alliance. Available at: www.jla.nihr.ac.uk\/top-10-priorities\/. Accessed 11 Jan 2020."},{"key":"1398_CR20","unstructured":"Rare Inherited Anaemias | James Lind Alliance. Available at: www.jla.nihr.ac.uk\/priority-setting-partnerships\/rare-inherited-anaemias\/. Accessed 11 Jan 2020."},{"key":"1398_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1750-1172-8-61","volume":"8","author":"P Davila-Seijo","year":"2013","unstructured":"Davila-Seijo P, Hern\u00e1ndez-Mart\u00edn A, Morcillo-Makow E, de Lucas R, Dom\u00ednguez E, Romero N, et al. Prioritization of therapy uncertainties in Dystrophic Epidermolysis Bullosa: where should research direct to? an example of priority setting partnership in very rare disorders. Orphanet J Rare Dis. 2013;8:61.","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"1398_CR22","doi-asserted-by":"publisher","first-page":"e026573","DOI":"10.1136\/bmjopen-2018-026573","volume":"9","author":"S Mollan","year":"2019","unstructured":"Mollan S, Hemmings K, Herd CP, Denton A, Williamson S, Sinclair AJ. What are the research priorities for idiopathic intracranial hypertension? A priority setting partnership between patients and healthcare professionals. BMJ Open. 2019;9(3):e026573.","journal-title":"BMJ Open"},{"issue":"1","key":"1398_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11914-016-0299-y","volume":"14","author":"IH Thomas","year":"2016","unstructured":"Thomas IH, DiMeglio LA. Advances in the classification and treatment of osteogenesis imperfecta. Curr Osteoporos Rep. 2016;14(1):1\u20139.","journal-title":"Curr Osteoporos Rep"},{"issue":"5","key":"1398_CR24","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s11914-016-0317-0","volume":"14","author":"C Robinson","year":"2016","unstructured":"Robinson C, Collins MT, Boyce AM. Fibrous Dysplasia\/McCune-Albright Syndrome: Clinical and Translational Perspectives. Curr Osteoporos Rep. 2016;14(5):178\u201386.","journal-title":"Curr Osteoporos Rep"},{"issue":"7","key":"1398_CR25","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1002\/jbmr.340","volume":"26","author":"TO Carpenter","year":"2011","unstructured":"Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician's guide to X-linked hypophosphatemia. J Bone Miner Res. 2011;26(7):1381\u20138.","journal-title":"J Bone Miner Res"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01398-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-020-01398-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01398-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T19:49:26Z","timestamp":1621367366000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01398-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,19]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1398"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01398-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-20724\/v1","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,19]]},"assertion":[{"value":"31 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Following guidance published by JLA and NHS National Patient Safety Agency National Research Ethics Service, this work required no ethics approval.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors give consent to publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MKJ has received honoraria, unrestricted research grants, travel and\/or subsistence expenses from: Mereo Biopharma and Kyowa Kirin Hakin. JW received speaker\u2019s honoraria from Eli Lilly and Sandoz, grant funding from Alexion and Immunodiagnostic Systems, donation of drug from Eli Lilly, Prostrakan (Kyowa Kirin) and Consilient for clinical studies, donation of assay kits from Biomedica, consulting fees from Shire, Mereo Biopharma, Kyowa Kirin, UCB Pharma and PharmaCosmos. JW is also a local PI and TSC member for Topaz study as well as a DMC member for Asteroid study. RK is a member of advisory board for the UK Brittle Bone Society and Kyowa Kirin, has received research support from Kyowa Kirin and Mereo BioPharma as well as consultancy fees from Kyowa Kirin.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"117"}}